Liraglutide exerts protective effects on MASLD independently of lipophagy, and the combination with kombucha presents no additional advantage
DOI:
https://doi.org/10.34119/bjhrv9n1-082Keywords:
MASLD, lipophagy, liraglutide, kombuchaAbstract
Introduction: Metabolic dysfunction – associated steatotic liver disease (MASLD) has a high global prevalence, requiring effective therapeutic options. This study investigated the effects of liraglutide and kombucha, alone and in combination, in a murine model of high-fat diet (HFD)-induced MASLD. Methodology: Metabolic parameters, body composition, liver histology, lipid profile, and markers of lipophagy were evaluated. Results: The results demonstrate that liraglutide reduced body weight, fat mass, and lean mass, as well as food and caloric intake, fasting blood glucose, hepatic triglycerides (TG), steatosis and fibrosis, improved the lipid profile and glucose tolerance, and increased lysosomal acid lipase (LAL) expression in the liver. Kombucha reduced lean mass, liver steatosis, hepatic TG, food and caloric intake, fasting blood glucose, plasma low-density lipoprotein cholesterol (LDL-C), and liver fibrosis, in addition to improving glucose tolerance. However, the combination of treatments did not show synergistic effects superior to those of liraglutide alone. Although liraglutide independently impacted LAL expression, none of the other lipophagy markers were modulated in the liver. Conclusion: It is concluded that both liraglutide and kombucha are valid strategies for mitigating MASLD, but the combination does not offer superior advantages over liraglutide monotherapy.
References
ABACI, N. et al. Kombucha – An ancient fermented beverage with desired bioactivities: a narrowed review. Food Chemistry: X, [S.L.], v. 14, p. 100302, jun. 2022. http://doi.org/10.1016/j.fochx.2022.100302.
AGOUNI, A. et al. In vivo differential effects of fasting, re-feeding, insulin and insulin stimulation time course on insulin signaling pathway components in peripheral tissues. Biochemical And Biophysical Research Communications, [S.L.], v. 401, n. 1, p. 104-111, out. 2010. http://doi.org/10.1016/j.bbrc.2010.09.018.
AHMED, L. et al. Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: role of lps/tlr4 and autophagy pathways. European Journal Of Pharmacology, [S.L.], v. 887, p. 173461, nov. 2020. http://doi.org/10.1016/j.ejphar.2020.173461.
ALRUWAILI, H. et al. Clinical Impact of Liraglutide as a Treatment of Obesity. Clinical Pharmacology: Advances and Applications, [S.L.], v. 13, p. 53-60, mar. 2021. http://doi.org/10.2147/CPAA.S276085.
ANDRIKOPOULOS, S. et al. Evaluating the glucose tolerance test in mice. American Journal Of Physiology-Endocrinology And Metabolism, [S.L.], v. 295, n. 6, p. 1323-1332, dez. 2008. http://doi.org/10.1152/ajpendo.90617.2008.
ARAUJO, L. et al. Uncaria tomentosa improves insulin sensitivity and inflammation in experimental NAFLD. Scientific Reports, [S.L.], v. 8, n. 1, p. 11013, 20 jul. 2018. http://doi.org/10.1038/s41598-018-29044-y.
ARMSTRONG, M. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet, [S.L.], v. 387, n. 10019, p. 679-690, fev. 2016. http://doi.org/10.1016/S0140-6736(15)00803-X.
BELLASSOUED, K. et al. Protective effect of kombucha on rats fed a hypercholesterolemic diet is mediated by its antioxidant activity. Pharmaceutical Biology, [S.L.], v. 53, n. 11, p. 1699-1709, 5 maio 2015. http://doi.org/10.3109/13880209.2014.1001408.
BUGÁňOVÁ, M. et al. The effects of liraglutide in mice with diet-induced obesity studied by metabolomics. Journal Of Endocrinology, [S.L.], v. 233, n. 1, p. 93-104, abr. 2017. http://doi.org/10.1530/JOE-16-0478.
COURRÈGES, J. et al. Beneficial effects of once‐daily liraglutide, a human glucagon‐like peptide‐1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabetic Medicine, [S.L.], v. 25, n. 9, p. 1129-1131, 29 ago. 2008. http://doi.org/10.1111/j.1464-5491.2008.02484.x.
DARMAWAN, A. et al. Effect of rosella-based kombucha tea on the lipid profile on hyperlipidemic rats (Rattus norvegicus). Niche Journal Of Tropical Biology, [S.L.], v. 1, n. 2, p. 42, 30 nov. 2018. http://doi.org/10.14710/niche.1.2.42-47.
DIKIC, I. et al. Mechanism and medical implications of mammalian autophagy. Nature Reviews Molecular Cell Biology, [S.L.], v. 19, n. 6, p. 349-364, 4 abr. 2018. http://doi.org/10.1038/s41580-018-0003-4.
FANG, Y. et al. Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway. Frontiers In Cell And Developmental Biology, [S.L.], v. 8, p. 1-15, 27 nov. 2020. http://doi.org/10.3389/fcell.2020.602574.
FARR, O. et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia, [S.L.], v. 59, n. 5, p. 954-965, 1 fev. 2016. http://doi.org/10.1007/s00125-016-3874-y.
FASANO, T. et al. Lysosomal lipase deficiency: molecular characterization of eleven patients with wolman or cholesteryl ester storage disease. Molecular Genetics And Metabolism, [S.L.], v. 105, n. 3, p. 450-456, mar. 2012. http://doi.org/10.1016/j.ymgme.2011.12.008.
FOLCH, J. et al. A simple method for the isolation and purification of total lipides from animal tissues. Journal Of Biological Chemistry, [s. l], v. 1, n. 226, p. 497-509, 1957. https://pubmed.ncbi.nlm.nih.gov/13428781/.
FRIEDEWALD, W. et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, [s. l], v. 6, n. 18, p. 499-502, 1972. https://pubmed.ncbi.nlm.nih.gov/4337382/.
GAO, H. et al. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease. Biological & Pharmaceutical Bulletin, [S.L.], v. 38, n. 5, p. 694-702, 2015. http://doi.org/10.1248/bpb.b14-00505.
GLUCHOWSKI, N. et al. Lipid droplets and liver disease: from basic biology to clinical implications. Nature Reviews Gastroenterology & Hepatology, [S.L.], v. 14, n. 6, p. 343-355, 21 abr. 2017. http://doi.org/10.1038/nrgastro.2017.32.
GOMARASCHI, M. et al. Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: evidence in nafld patients and cell cultures. Biochimica Et Biophysica Acta (Bba) - Molecular And Cell Biology Of Lipids, [S.L.], v. 1864, n. 12, p. 158523, dez. 2019. http://doi.org/10.1016/j.bbalip.2019.158523
JAKUBEK, P. et al. Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies. Internal And Emergency Medicine, [S.L.], v. 19, n. 5, p. 1473-1491, 6 jul. 2024. http://doi.org/10.1007/s11739-024-03700-w.
JI, J. et al. Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. Bioengineered, [S.L.], v. 13, n. 3, p. 5091-5102, 14 fev. 2022. http://doi.org/10.1080/21655979.2022.2036902.
LARSEN, P. et al. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience, [S.L.], v. 77, n. 1, p. 257-270, jan. 1997. http://doi.org/10.1016/s0306-4522(96)00434-4
LEE, C. et al. Hepatoprotective Effect of Kombucha Tea in Rodent Model of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. International Journal Of Molecular Sciences, [S.L.], v. 20, n. 9, p. 2369, 13 maio 2019. http://doi.org/10.3390/ijms20092369.
LEOPOLD, C. et al. Hepatocyte-specific lysosomal acid lipase deficiency protects mice from diet-induced obesity but promotes hepatic inflammation. Biochimica Et Biophysica Acta (Bba) - Molecular And Cell Biology Of Lipids, [S.L.], v. 1864, n. 4, p. 500-511, abr. 2019. http://doi.org/10.1016/j.bbalip.2019.01.007.
LIAO, Z. et al. Liraglutide Improves Nonalcoholic Fatty Liver Disease in Diabetic Mice by Activating Autophagy Through AMPK/mTOR Signaling Pathway. Diabetes, Metabolic Syndrome And Obesity, [S.L.], v. 17, p. 575-584, fev. 2024. http://doi.org/10.2147/DMSO.S447182
LIU, Q. et al. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice. Life Sciences, [S.L.], v. 261, p. 118457, nov. 2020. http://doi.org/10.1016/j.lfs.2020.118457.
LOPRESTI, M. et al. Hepatic lysosomal acid lipase overexpression worsens hepatic inflammation in mice fed a Western diet. Journal Of Lipid Research, [S.L.], v. 62, p. 100133, 2021. http://doi.org/10.1016/j.jlr.2021.100133.
MARTINEZ-LOPEZ, N. et al. System-wide Benefits of Intermeal Fasting by Autophagy. Cell Metabolism, [S.L.], v. 26, n. 6, p. 856-871, dez. 2017. http://doi.org/10.1016/j.cmet.2017.09.020.
MEHLEM, A. et al. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nature Protocols, [S.L.], v. 8, n. 6, p. 1149-1154, 23 maio 2013. http://doi.org/10.1038/nprot.2013.055.
MIAO, L. et al. Current status and future trends of the global burden of MASLD. Trends In Endocrinology & Metabolism, [S.L.], v. 35, n. 8, p. 697-707, ago. 2024. http://doi.org/10.1016/j.tem.2024.02.007.
MIZUSHIMA, N. et al. In Vivo Analysis of Autophagy in Response to Nutrient Starvation Using Transgenic Mice Expressing a Fluorescent Autophagosome Marker. Molecular Biology Of The Cell, [S.L.], v. 15, n. 3, p. 1101-1111, mar. 2004. http://doi.org/10.1091/mbc.e03-09-0704.
MOREIRA, G. et al. Kombucha tea improves glucose tolerance and reduces hepatic steatosis in obese mice. Biomedicine & Pharmacotherapy, [S.L.], v. 155, p. 113660, nov. 2022. http://doi.org/10.1016/j.biopha.2022.113660.
MOREIRA, G. et al. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. The Journal Of Nutritional Biochemistry, [S.L.], v. 62, p. 143-154, dez. 2018. http://doi.org/10.1016/j.jnutbio.2018.07.009
MOREIRA, R. et al. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: a joint position statement from the brazilian society of endocrinology and metabolism (sbem), brazilian society of hepatology (sbh), and brazilian association for the study of obesity and metabolic syndrome (abeso). Archives Of Endocrinology And Metabolism, [S.L.], v. 67, n. 6, p. 1-23, 2023. http://doi.org/10.20945/2359-4292-2023-0123.
RAMÍREZ-ZACARÍAS, J. et al. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with oil red O. Histochemistry, [S.L.], v. 97, n. 6, p. 493-497, jul. 1992. http://doi.org/10.1007/BF00316069.
SANGRO, P. et al. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. Journal Of Physiology And Biochemistry, [S.L.], v. 79, n. 4, p. 869-879, 28 mar. 2023. https://doi.org/10.1007/s13105-023-00954-4
SHTEYER, E. et al. Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease. International Journal Of Molecular Sciences, [S.L.], v. 17, n. 3, p. 312, 27 fev. 2016. http://doi.org/10.3390/ijms17030312.
SILVA, F. et al. Dexamethasone-Induced Adipose Tissue Redistribution and Metabolic Changes: is gene expression the main factor? an animal model of chronic hypercortisolism. Biomedicines, [S.L.], v. 10, n. 9, p. 2328, 19 set. 2022. http://doi.org/10.3390/biomedicines10092328.
STURIS, J. et al. GLP‐1 derivative liraglutide in rats with β‐cell deficiencies: influence of metabolic state on β⠰cell mass dynamics. British Journal Of Pharmacology, [S.L.], v. 140, n. 1, p. 123-132, set. 2003. http://doi.org/10.1038/sj.bjp.0705397.
TAN, Y. et al. Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes. Frontiers In Endocrinology, [S.L.], v. 13, p. 1-8, 10 ago. 2022. http://doi.org/10.3389/fendo.2022.935180.
TOVOLI, F. et al. A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. International Journal Of Molecular Sciences, [S.L.], v. 18, n. 6, p. 1134, 25 maio 2017. http://doi.org/10.3390/ijms18061134.
URRUTIA, M. et al. Effects of supplementation with kombucha and green banana flour on Wistar rats fed with a cafeteria diet. Heliyon, [S.L.], v. 7, n. 5, p. 07081, maio 2021. http://doi.org/10.1016/j.heliyon.2021.e07081.
VARANASI, A. et al. Clinical Use of Liraglutide in Type 2 Diabetes and its Effects on Cardiovascular Risk Factors. Endocrine Practice, [S.L.], v. 18, n. 2, p. 140-145, mar. 2012. http://doi.org/10.4158/EP11169.OR
WANG, Y. et al. Hepatoprotective effects of kombucha tea: identification of functional strains and quantification of functional components. Journal Of The Science Of Food And Agriculture, [S.L.], v. 94, n. 2, p. 265-272, jul. 2013. http://doi.org/10.1002/jsfa.6245
YANAI, H. et al. Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. International Journal Of Molecular Sciences, [S.L.], v. 24, n. 20, p. 15473, 23 out. 2023. http://doi.org/10.3390/ijms242015473.
YANG, M. et al. Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System. Frontiers In Pharmacology, [S.L.], v. 11, p. 1, 8 abr. 2020. http://doi.org/10.3389/fphar.2020.00432.
YANG, P. et al. Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway. Diabetes, Metabolic Syndrome And Obesity: Targets and Therapy, [S.L.], v. 12, p. 1013-1021, jul. 2019. http://doi.org/10.2147/DMSO.S206867.
ZECHNER, R. et al. Cytosolic lipolysis and lipophagy: two sides of the same coin. Nature Reviews Molecular Cell Biology, [S.L.], v. 18, n. 11, p. 671-684, 30 ago. 2017. http://doi.org/10.1038/nrm.2017.76.
ZHANG, S. et al. The regulation, function, and role of lipophagy, a form of selective autophagy, in metabolic disorders. Cell Death & Disease, [S.L.], v. 13, n. 2, p. 1, 8 fev. 2022. http://doi.org/10.1038/s41419-022-04593-3.
